Literature DB >> 26547571

Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia.

Adam M Mendizabal1,2, Naji Younes1, Paul H Levine3,4.   

Abstract

Developing countries have a younger population of CML patients than developed countries. Patterns of age at diagnosis and incidence by geography and gross national income (GNI) are not well understood. A population-based descriptive study was conducted using data from the International Agency for Research on Cancer's population-based registry compilation. Geographical regions were classified according to the United Nations World Macro Regions and Components. Age-Standardized Incidence Rates (ASR) were adjusted to the World Standard Population. Poisson regression was used to assess age-specific interactions. 57.2% were male among 33,690 diagnoses. Median age at diagnosis was lowest in Africa and Asia (47 years) and highest in Oceania (72 years). ASR was lowest in African males (0.61 per 100,000) and Asian females (0.55 per 100,000) and highest in Oceania males and females (1.78 and 0.96 per 100,000, respectively). A significant interaction (p < 0.0001) between age (<50 years and >50 years) and region exists; no significant differences were seen by region in the <50 age-group while significant differences by region exist in the >50 age group. Population-based estimates suggest that the median age at diagnosis and incidence varies by region. Geographic and income heterogeneity suggest an important effect of environment that warrants further studies.

Entities:  

Keywords:  Age at diagnosis; Chronic myeloid leukemia; Geography; Incidence

Mesh:

Substances:

Year:  2015        PMID: 26547571     DOI: 10.1007/s12185-015-1893-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  21 in total

Review 1.  Chronic myeloid leukemia.

Authors:  C L Sawyers
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  Lympho-hemopoietic malignancies in India.

Authors:  Manisha Bhutani; Amish Vora; Lalit Kumar; Vinod Kochupillai
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

3.  Leukemia in Hiroshima atomic bomb survivors.

Authors:  R HEYSSEL; A B BRILL; L A WOODBURY; E T NISHIMURA; T GHOSE; T HOSHINO; M YAMASAKI
Journal:  Blood       Date:  1960-03       Impact factor: 22.113

4.  Geographic patterns of leukemia in the United States.

Authors:  A Blair; J F Fraumeni; T J Mason
Journal:  J Chronic Dis       Date:  1980

5.  Death certificate study of leukemia among farmers from Wisconsin.

Authors:  A Blair; D W White
Journal:  J Natl Cancer Inst       Date:  1981-06       Impact factor: 13.506

6.  Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era.

Authors:  Saad Z Usmani; Shakeeb A Yunus; Yasser Jamal
Journal:  Asian Pac J Cancer Prev       Date:  2009

7.  Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.

Authors:  Zeba Aziz; Javaid Iqbal; Mohammad Akram; Sarah Saeed
Journal:  Cancer       Date:  2007-03-15       Impact factor: 6.860

Review 8.  Specific targeted therapy of chronic myelogenous leukemia with imatinib.

Authors:  Michael W N Deininger; Brian J Druker
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

9.  Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006.

Authors:  Ai-Hua Wang; Yan-Yan Wang; Yu Yao; Zi-Zhen Xu; Li Zhou; Li Wang; Li Zhang; Yu Chen; Zhi-Xiang Shen; Jiong Hu; Jun-Min Li
Journal:  J Exp Clin Cancer Res       Date:  2010-03-03

10.  Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program.

Authors:  Ebru Tekinturhan; Etienne Audureau; Marie-Pierre Tavolacci; Patricia Garcia-Gonzalez; Joël Ladner; Joseph Saba
Journal:  BMC Health Serv Res       Date:  2013-08-10       Impact factor: 2.655

View more
  6 in total

1.  Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.

Authors:  Hirohisa Nakamae; Shin Fujisawa; Michinori Ogura; Toshiki Uchida; Yasushi Onishi; Masafumi Taniwaki; Atae Utsunomiya; Kosei Matsue; Yasushi Takamatsu; Kensuke Usuki; Mitsune Tanimoto; Yoji Ishida; Kazuteru Ohashi; Li Li; Masafumi Miyoshi
Journal:  Int J Hematol       Date:  2017-03-24       Impact factor: 2.490

Review 2.  Lifelong TKI therapy: how to manage cardiovascular and other risks.

Authors:  Michael J Mauro
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.

Authors:  E Dianne Pulte; Haiyan Chen; Lauren S L Price; Ramadevi Gudi; Hongshan Li; Olanrewaju O Okusanya; Lian Ma; Lisa Rodriguez; Jonathon Vallejo; Kelly J Norsworthy; R Angelo de Claro; Marc R Theoret; Richard Pazdur
Journal:  Oncologist       Date:  2022-03-04       Impact factor: 5.837

4.  Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment.

Authors:  Oliver Henke; Priscus John Mapendo; Elifuraha Wilson Mkwizu; Philipp le Coutre
Journal:  Ecancermedicalscience       Date:  2020-08-18

5.  Incidence and spatial distribution of Chronic Myeloid Leukemia by regions of economic development in the state of Pernambuco, Brazil.

Authors:  Washington Batista das Neves; Ana Maria de Brito; Andreza Pâmela Vasconcelos; Fárida Coeli de Barros Correia Melo; Raul Antônio Morais Melo
Journal:  Hematol Transfus Cell Ther       Date:  2019-03-28

6.  Reply to Letter by Dr. Christoph Kupferschmid: Commentary on "Countries with high circumcision prevalence have lower prostate cancer mortality".

Authors:  Mitchell S Wachtel; Shengping Yang; Brian J Morris
Journal:  Asian J Androl       Date:  2016 Nov-Dec       Impact factor: 3.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.